{"preliminary_commentary":{"by_channel":{"podcast":5,"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05211895\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"PACIFIC-8","nct_id":"NCT05211895","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=pacific-8-nct05211895. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"PACIFIC-8","arms":[{"description":"Durvalumab and domvanalimab as an IV infusion q4w, starting on Day 1 for up to a maximum of 12 months","label":"Arm A: Durvalumab + Domvanalimab","type":"EXPERIMENTAL"},{"description":"Durvalumab + placebo as an IV infusion q4w starting on Day 1 for up to a maximum of 12 months","label":"Arm B: Durvalumab + Placebo","type":"ACTIVE_COMPARATOR"}],"collaborators":["Arcus Biosciences, Inc."],"completion_date":{"date":"2027-09-08","type":"ESTIMATED"},"conditions":["Non-Small Cell Lung Cancer"],"enrollment":{"count":791,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Durvalumab","otherNames":[],"type":"DRUG"},{"name":"Domvanalimab","otherNames":[],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"OTHER"}],"last_update":"2026-08-28","lead_sponsor":"AstraZeneca","official_title":"A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab Plus Domvanalimab(AB154) in Participants With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease Has Not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-08-10","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS)","timeFrame":"Up to 5 years after randomization"}],"references":[],"start_date":{"date":"2022-02-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC","url":"https://clinicaltrials.gov/study/NCT05211895"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/pacific-8-nct05211895"}